Who said GT20029 would be applied only few times per month? Research/Science 9/6/2022
The conversation discusses the safety and effectiveness of a hair loss drug, GT20029, and the possibility of infrequent application, with users hoping for once-daily use and speculating on the drug's duration of effect on the scalp. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
View this post in the Community →
Similar Community Posts Join
6 / 218 resultscommunity It’s over. NOTHING has worked.
A user who has been trying various treatments for hair loss for four years, with no success. Suggestions include use of minoxidil, finasteride, RU58841, microneedling, supplements and multivitamins, lifestyle changes, scalp biopsy, and SMP.
community Why I Will be Accepting Baldness
User decides to accept baldness due to mental health issues with finasteride. Others suggest considering hair systems, topical finasteride, or RU58841 as alternatives.
community AnagenInc says GT20029 is possible now
AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.
community Boys I am just a gonner. What on earth is my scalp even going through. Looks like world war 3. Pyril 3 months. Topical melitonin/progesterone/fin, dut, fin, oral min, laser trash, anus stimulation. Nothing. Donor area is decimated 😂.
Treating Seborrheic Dermatitis, a fungal scalp condition which can cause hair loss. Treatments discussed include antifungal shampoos, cold showers, exfoliating the scalp, taking Vitamin D, and stimulating the prostate through the anus.
community cosmeRNA finally now it's pyrilutamide turn
Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.
community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
Related Research
5 / 5 results
research Topical Solutions for Androgenetic Alopecia: Evaluating Efficacy and Safety
Topical treatments for hair loss can be effective but need careful safety evaluation.
research What's New in Therapy for Male Androgenetic Alopecia?
research Androgens and Androgen Receptor in the Management of Skin Diseases
Understanding how androgens and their receptors work can lead to improved treatments for skin diseases.
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.